Regeneron Pharmaceuticals

AUG 20, 2026 · PHASE 3 TRIAL

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes have not yet been reported.

AUG 20, 2026 · PHASE 2 TRIAL

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

ClinicalTrials.gov

This is a Phase 2 interventional trial registration with planned enrollment of 360 participants, currently recruiting, designed to assess safety, tolerability, and preliminary efficacy of olatorepatide in overweight/obesity without diabetes; no results are yet reported.

AUG 19, 2026 · PHASE 3 TRIAL

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

ClinicalTrials.gov

This is an ongoing Phase 3 trial registration with no results reported; it describes a planned interventional study in a clinically important area but carries no efficacy or safety data yet.

AUG 13, 2026 · PHASE 2 TRIAL

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov

This is a Phase 2 trial registration with no results reported; it describes a planned study of experimental agents in advanced NSCLC with surrogate endpoints (objective response by RECIST), requiring completion and results publication before evidence strength can be assessed.